International Stem Cell Corporation (OTCQB: ISCO), a
clinical stage biotechnology company developing novel stem cell-based
therapies, recently announced that it has entered into an agreement with the
Florey Institute of Neuroscience and Mental Health (Florey) to conduct a Phase
I/IIa clinical trial, dose escalation trial of human parthenogenetic stem
cells-derived neural stem cells (ISC-hpNSC) in Parkinson’s patients. The Florey
is viewed by the medical community as one of the world’s leading brain research
centers. With the largest neuroscience research team in Australia at its side,
both parties’ collaborative efforts are now underway.
Director of the Movement Disorders Service at the Royal
Melbourne Hospital, Dr. Andrew Evans, M.D., has assumed the duties that come
with being named the study’s principal investigator. Dr. Evans has published
extensively on Parkinson’s, addressing symptoms while leading several clinical
research trials.
“We recently received authorization to initiate Phase I/IIa
and now we are moving forward towards formal engagement of the clinical site to
conduct this study. We are excited to work together with the Florey to conduct
the clinical trials of ISC-hpNSC at the Royal Melbourne Hospital,” commented
Russell Kern, PhD, executive vice president and chief scientific officer at
International Stem Cell Corporation. “We expect to enroll all patients into the
clinical trial in Q1 2016 and provide interim results in October 2016.”
ISC-hpNSC consists of a highly pure population of neural
stem cells derived from human parthenogenetic stem cells. ISC-hpNSC are a
suspension of clinical grade cells manufactured under cGMP conditions that have
undergone stringent quality control measures and are clear of any microbial and
viral contaminants.
ISCO’s resources and efforts are aimed at therapeutic
applications of human parthenogenetic stem cells (hpSCs) and the development
and commercialization of cell-based research and cosmetic products.
Parthenogenesis, ISCO’s core technology, results in the creation of pluripotent
human stem cells from unfertilized oocytes. hpSCs avoid ethical issues
associated with the use or destruction of viable human embryos. Company
scientists have created the first parthenogenetic, homozygous stem cell line
that can be a source of therapeutic cells for hundreds of millions of
individuals of various genders, ages and racial backgrounds with minimal immune
rejection after transplantation.
For more information, visit www.internationalstemcell.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
